Dexcom
Builds continuous glucose monitors for diabetes care and broader metabolic-health tracking.
Something off on this page? Send us feedback.
Profile
Produces continuous glucose monitors for diabetes and metabolic health, led by prescription G7 systems and the over-the-counter Stelo biosensor. Revenue comes mainly from recurring disposable-sensor sales in the United States, supported by apps, cloud reporting, and insulin-delivery integrations, with access tied to device approvals and reimbursement.
Designs and sells wearable continuous glucose monitoring systems that send glucose readings and alerts to apps, receivers, and connected insulin-delivery devices. The prescription portfolio is shifting from Dexcom G6 to Dexcom G7 and G7 15 Day, while Dexcom ONE+ serves selected international markets and Stelo brings over-the-counter glucose sensing to people who do not use insulin. Most revenue comes from the United States, through distributors and direct channels.
Combines disposable sensors with reusable hardware, cloud reporting, remote-sharing software, and integrations with insulin pumps and smart pens. Frequent sensor replacement creates recurring product demand, while connected-device compatibility broadens how readings support care. Commercial access depends on medical-device clearances and public and private reimbursement; manufacturing quality is tightly regulated, and some components come from single or sole sources.
Company facts
Categories
Key statistics
Year to date +36.5% · Average volume (30d) 5.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 4, 2026 | Argus Research | Reiterate | Buy | $96 | |
| Aug 3, 2026 | Canaccord Genuity | Reiterate | Buy | $82 | $90 |
| Aug 3, 2026 | RBC Capital | Target | $85 | $90 | |
| Jul 31, 2026 | Raymond James | Reiterate | Strong Buy | $91 | $94 |
| Jul 31, 2026 | Piper Sandler | Reiterate | Overweight | $88 | $95 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $0.61 | $0.70 | +14.6% | $1.29B | $1.31B | +1.4% | +11.95% |
| Apr 30, 2026Q1 FY26 | $0.47 | $0.56 | +20.3% | $1.17B | $1.19B | +1.5% | +3.02% |
| Feb 12, 2026Q4 FY25 | $0.65 | $0.68 | +4.6% | $1.25B | $1.26B | +0.9% | +7.59% |
| Oct 30, 2025Q3 FY25 | $0.58 | $0.61 | +5.9% | $1.18B | $1.21B | +2.2% | −14.63% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.16B | $1.21B | $1.26B | $1.19B | $1.31B | |
| Gross profit | $589.0M | $688.8M | $731.4M | $792.7M | $750.3M | $830.0M | |
| Operating income | $133.7M | $212.6M | $242.5M | $323.0M | $255.3M | $318.3M | |
| Net income | $105.4M | $179.8M | $283.8M | $267.3M | $199.5M | $249.1M | |
| Diluted EPS | $0.27 | $0.45 | $0.70 | $0.68 | $0.51 | $0.64 | |
| Gross margin | 56.9% | 59.5% | 60.5% | 62.9% | 62.9% | 63.4% | |
| Operating margin | 12.9% | 18.4% | 20.1% | 25.6% | 21.4% | 24.3% |
Fiscal years (4-quarter sums)FY21 $2.45B · FY22 $2.91B · FY23 $3.62B · FY24 $4.03B · FY25 $4.66B
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $1.95B · Total debt $1.40B · Total assets $6.46B · Shareholders' equity $2.62B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 377.36M · Float 376.05M · 99.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 38.24M | 10.13% | 13F | Aug 7, 2026 |
| Vanguard Capital Management LLC | 25.21M | 6.68% | 13F | Aug 13, 2026 |
| Vanguard Portfolio Management LLC | 19.66M | 5.21% | 13F | Aug 13, 2026 |
| State Street Corp | 18.38M | 4.87% | 13F | Aug 7, 2026 |
| Invesco Ltd. | 15.29M | 4.05% | 13F | Aug 14, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Sadie Stern | officer: EVP Chief People & Culture Off | −2,565 | $88.37 |
| Aug 20, 2026 | Kevin R. Sayer | director, officer: Executive Chair | −26,756 | $90.01 |
| Aug 14, 2026 | Michael Jon Brown | officer: EVP Chief Legal Compliance Off | −1,700 | $91.93 |
| Aug 12, 2026 | Bridgette P. Heller | director | −1,012 | $88.29 |
| Aug 3, 2026 | Mark G. Foletta | director | −2,000 | $85.32 |
Peers
- Abbott
Global CGM leader; Lingo and Libre Rio contest Stelo directly.
- Medtronic
MiniMed 780G AID + Simplera/Instinct CGM; diabetes unit spinning out.
- Insulet
Omnipod 5 AID pump: integrates both DexCom G6/G7 and Abbott Libre.
- Tandem Diabetes Care
t:slim / Mobi AID pumps support DexCom and Abbott CGMs; $1B in 2025.
- Senseonics
Eversense 365: only 1-year implantable iCGM; 49.5% patients from DexCom.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Dexcom | $90.77 | −0.06% | $34.27B | 35.9 | 32.4 | 6.9 | +13.1% |
| Abbott | $112.20 | −0.22% | $194.62B | 36.2 | 19.4 | 4.2 | +13.0% |
| Medtronic | $91.58 | +0.42% | $116.78B | 24.5 | 15.3 | 3.2 | +9.9% |
| Insulet | $145.31 | +0.11% | $10.05B | 27.1 | 21.0 | 3.3 | +23.5% |
| Tandem Diabetes Care | $21.16 | −1.26% | $1.47B | — | — | 1.4 | +5.8% |
| Senseonics | $9.37 | +0.54% | $389.9M | — | — | 8.0 | +118.1% |
| Median | 27.1 | 19.4 | 3.3 | +13.0% |